Inside the research
Veracyte, Inc.
VCYT Research profile · latest available data
Price overview
$45.43
▼ -3.11 (-6.4%)
| 52w hi | $60.49 |
|---|---|
| 52w lo | $30.01 |
| Vol | 1.73M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.17
| Short | -0.48 |
|---|---|
| Medium | -0.03 |
| Long | +0.17 |
computed 2026-09-27
Key fundamentals
Veracyte, Inc.
Healthcare · Diagnostics & Research
| Market cap | $3.65B |
|---|---|
| Enterprise value | $3.21B |
| Trailing P/E | 32.45x |
| Forward P/E | 23.29x |
| EV / EBITDA | 28.25x |
| P / S (ttm) | 6.50x |
| Profit margin | 20.4% |
| Return on equity | 8.8% |
| Revenue growth | +15.5% |
| Debt / equity | 2.89 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.24 | |
| Sector | +0.08 | |
| Technical | -0.18 | |
| Earnings | +0.00 | |
| Sentiment | -0.24 |
macro × 1.00 · 2026-09-27
Business overview
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Risk Metrics
| Beta vs SPX | 1.33 |
|---|---|
| Corr SPX | 0.37 |
| Annual vol | 58.0% |
| Annual ret | +29.7% |
| Sharpe | 0.51 |
| Max DD | -50.1% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-30 | Earnings Release, Exhibits | read |
| 2026-06-11 | Officer / Director Change, Shareholder Vote | read |
| 2026-05-05 | Earnings Release, Exhibits | read |
| 2026-03-16 | Officer / Director Change | read |
| 2026-02-25 | Earnings Release, Exhibits | read |
| 2026-01-12 | Earnings Release, Exhibits | read |
| 2025-11-04 | Earnings Release, Exhibits | read |
| 2025-08-06 | Earnings Release, Exhibits | read |
| 2025-06-18 | Officer / Director Change, Shareholder Vote… | read |
| 2025-05-07 | Earnings Release, Exhibits | read |
| 2025-02-24 | Earnings Release, Exhibits | read |
| 2024-11-06 | Earnings Release, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-18 | EASTHAM KARIN | Sell | 3.20K | $168.91K | |
| 2026-06-18 | EASTHAM KARIN | Sell | 529 | $28.33K | |
| 2026-06-11 | JONES EVAN/ FA | Grant | 5.27K | — | |
| 2026-06-11 | Shafer David Brent | Grant | 5.27K | — | |
| 2026-06-11 | Barr Eliav | Grant | 5.27K | — | |
| 2026-06-11 | Holstein Jens | Grant | 5.27K | — | |
| 2026-06-11 | Bhanji Muna | Grant | 5.27K | — | |
| 2026-06-11 | Miller Thomas F. | Grant | 5.27K | — | |
| 2026-06-11 | EPSTEIN ROBERT S | Grant | 5.27K | — | |
| 2026-06-11 | EASTHAM KARIN | Grant | 5.27K | — |
Flow & Concentration
| Insider 180d net | -$355.27K |
|---|---|
| Insider buys / sells | 0 / 4 |
| Insider bias | Neutral |
| 13F holders | 9 |
| Top-5 share | 98.8% |
| HHI | 3,624 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Fidelity / FMR LLC | $452.38M | 7.70M |
| State Street Corp | $275.95M | 4.70M |
| Ark Invest | $134.84M | 2.30M |
| Capital Research / Capital World | $26.43M | 450.01K |
| AQR Capital Management | $8.79M | 149.65K |
| Millennium Management | $7.16M | 121.98K |
| Bridgewater Associates | $3.42M | 58.29K |
| Citadel Advisors | $469.84K | 8.00K |
| T. Rowe Price Group | $6.44K | 109.61K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2013–2025 · 13 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $517.14M | +55.2% | |
| Gross profit | $229.68M | -23.0% | |
| Operating income | $16.14M | +0.0% | |
| Net income | $66.35M | +174.9% | |
| Cash from ops | $44.22M | +80.4% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $49.00 | $49.00 | $45.36 | $45.43 | 1.73M |
| Sep 24 | $43.66 | $48.95 | $43.51 | $48.54 | 2.88M |
| Sep 23 | $42.95 | $43.86 | $42.25 | $43.82 | 1.53M |
| Sep 22 | $41.76 | $43.74 | $41.31 | $43.36 | 1.47M |
| Sep 21 | $40.00 | $41.98 | $39.40 | $41.52 | 1.47M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →